Navigation Links
New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis

EXTON, Pa., Dec. 14 /PRNewswire/ -- BioTrends Research Group, Inc. released ChartTrends®: Biologics in Rheumatoid Arthritis, a syndicated publication offering comprehensive insight into the management of RA patients. The report is based on a comparison of self-reported treatment approaches (as reported by 208 Rheumatologists) with actual patient level data for over 1,000 RA patients who are currently being treated with biologic agents.

To be eligible for the audit, patients had to currently be treated with a biologic agent (UCB's Cimzia, Amgen/Wyeth's Enbrel, Abbott's Humira, Bristol Myers Squibb's Orencia , Centocor-Ortho Biotech's Remicade and Simponi, or Genentech's Rituxan). Each brand was represented by at least 98 patient charts and Rheumatologists were limited to one audit per brand. The aim of ChartTrends is to understand actual treatment algorithms for the biologic brands and to clearly understand the "patient types" being treated with these agents. The audit captured patient demographic variables, co-morbidities, concomitant medications (including DMARD dose and strategy), disease history from diagnosis, biologic initiation, dose titration, brand switching, current clinical status and results from the most recent laboratory and radiographic tests.

Among the audited patients, 30% had their disease classified as severe. 76% of the patients were female, average age was 54 and overall, patients had been followed by their current Rheumatologist for 54 months. The majority of patients are currently prescribed concomitant DMARD therapy, such as methotrexate, although the prevalence varied by brand. While Rheumatologists have reported a more aggressive use of biologic agents, this study confirms these reports by demonstrating that the time between original RA diagnosis and biologic initiation has decreased significantly over the past five years.

First line use was most common with Enbrel and Humira, while Rituxan and Orencia were more commonly later line choices. Despite an indication for use after DMARD failure, more than three quarters of the Orencia patients (n=155) were not started on the therapy until at least one TNF-alpha failure. The two new TNF-alpha treatments, UCB's Cimzia and Centocor Ortho-Biotech's Simponi, are drawing from both biologic naive and switch patients. These new products have significantly higher rates of prior authorization required compared to other biologic agents.

Physicians were also presented with three new agents currently under development for RA, Roche's Actemra, GSK's Arzerra and Pfizer's CP-690. Rheumatologists have greatest familiarity with Actemra, but expressed highest interest in CP-690. The newer TNF-alpha agents (Simponi and Cimzia) along with the alternate mechanism of action agents Orencia and Rituxan appear to be at greatest risk from new entrants into the RA biologic market.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. ( provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or

All company, brand, or product names contained in this document may be trademarks of their respective holders.

    Paul Callahan

SOURCE BioTrends Research Group, Inc.

SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014
2. Drug Candidates in Pipeline Offer Potential for Parkinsons Disease Therapeutics Market, Says Frost & Sullivan
3. Reportlinker Adds Medical Fiber Optics - A World Market Analysis
4. Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities
5. Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis
6. Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009
7. Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries)
8. Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis
9. Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective
10. Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis
11. Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review
Post Your Comments:
(Date:11/30/2015)... 2015   Royal Philips (NYSE: PHG ... first MRI guided user interface and automatic scan parameter ... MR Conditional implants, such as knee and hip replacements, ... Society of North America Annual Meeting (RSNA) . The ... confidence of this growing patient population. ScanWise Implant adds ...
(Date:11/30/2015)... -- North America was valued at ... a CAGR of 7.6% from 2015 to 2020. --> ... in 2014, and is expected to grow at a CAGR of ... new Market Research Report "North America Cardiac Output Monitoring Devices Market ... care, others) - Analysis And Forecast To 2020", the cardiac output ...
(Date:11/30/2015)... KONG, Nov. 30, 2015 (HK$,000)For the Six Months Ended 30 September 2015 ... Income , 421,979 , 384,242 , ... , 34,719 , (18.3) Medical Insurance ... , 16.1 Medical Devices and Accessories Sales , ... Chinese Herbal Medicines Sales , 2,822 , ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... According to an article published ... but slightly unusual choice to show her Instagram followers that the praise that they ... been pre-mature. Saying that she didn’t “want to mislead any mommy's who just had ...
(Date:11/30/2015)... Los Angeles, CA (PRWEB) , ... November 30, 2015 , ... ... hunger cravings that drive people to overeat are not necessarily caused by real hunger, ... brain that the stomach needs food. He notes that, while many patients are aware ...
(Date:11/30/2015)... ... November 30, 2015 , ... Cycling, running, and walking ... on extra meaning the morning of February 28, 2016. , That’s when the ... and thousands will exercise to help children and families at Joe DiMaggio Children’s ...
(Date:11/30/2015)... ... November 30, 2015 , ... RoamRight, a leading provider of travel ... Public Television’s Travel With Kids to promote family vacations around the world. The ... explore international destinations and educate families about the people and places of the world, ...
(Date:11/30/2015)... ... November 30, 2015 , ... A novel class of ... be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant ... that small molecule analogs that target the functions of SecA, a central part ...
Breaking Medicine News(10 mins):